Israel Englander’s NRX Pharmaceuticals NRXP Stock Holding History

Israel Englander’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.3K	Buy	+12,305	New	+$40.6K	﹤0.01%	5609
2025 Q1	–	Sell	-27,624	Closed	-$60.8K	–	6237
2024 Q4	$60.8K	Buy	+27,624	New	+$37.1K	﹤0.01%	5563
2023 Q4	–	Sell	-15,718	Closed	-$40.9K	–	6382
2023 Q3	$40.9K	Buy	+15,718	New	+$52.3K	﹤0.01%	5522
2022 Q3	–	Sell	-29,682	Closed	-$178K	–	7359
2022 Q2	$178K	Buy	+29,682	New	+$390K	﹤0.01%	5691
2022 Q1	–	Sell	-1,326	Closed	-$63K	–	7299
2021 Q4	$63K	Buy	+1,326	New	+$95.7K	﹤0.01%	6414

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Israel Englander's NRXP Position: Q2 2026 in Review

Israel Englander opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 12,305 shares worth $50.3K. The stake represents ﹤0.01% of the portfolio and ranks #5609 among its holdings. This is a return to the name: Israel Englander previously reported a position in NRXP as recently as Q4 2024.

Israel Englander first reported a position in NRXP in Q4 2021 and has held it in 5 quarters since. The position peaked at $178K in Q2 2022. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

Israel Englander held 12,305 shares of NRX Pharmaceuticals worth $50.3K as of Q2 2026.
NRX Pharmaceuticals was a new Israel Englander position in Q2 2026.
NRX Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5609 holding.
Israel Englander first reported a position in NRX Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
Israel Englander's NRX Pharmaceuticals position peaked at $178K in Q2 2022.
47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.